Shopping Cart
- Remove All
- Your shopping cart is currently empty
GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $113 | In Stock | |
5 mg | $289 | In Stock | |
10 mg | $396 | In Stock | |
25 mg | $653 | In Stock | |
50 mg | $892 | In Stock | |
100 mg | $1,230 | In Stock |
Description | GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA). |
In vivo | In the single ascending dose study, healthy, non-obese, and obese subjects received GS-9667 (30-1,800 mg; oral; single dose). In the multiple, ascending dose study, healthy, obese subjects received GS-9667 (600-2,400 mg QD, 1,200 mg BID, or 600 mg QID) for 14 days. Doses of GS-9667 ≥300 mg caused dose-dependent reductions in FFA levels that were reproducible over 14 days without evidence of desensitization or rebound. All doses were well tolerated. GS-9667 was rapidly absorbed and distributed; Steady-state concentrations were achieved within 3-5 days. The A(1) AR partial agonist GS-9667 reduced plasma FFA, exhibited linear kinetics, and was well-tolerated in healthy non-obese and obese subjects.[1] |
Alias | CVT-3619, CVT 3619 |
Molecular Weight | 461.51 |
Formula | C21H24FN5O4S |
Cas No. | 618380-90-8 |
Smiles | O[C@H]1[C@H](N2C=3C(N=C2)=C(N[C@H]4[C@H](O)CCC4)N=CN3)O[C@H](CSC5=C(F)C=CC=C5)[C@H]1O |
Relative Density. | 1.68 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 55 mg/mL (119.17 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.